Recombinant antibodies show several advantages in contrast to traditional monoclonal antibodies. This article will demonstrate that recombinant antibodies are the better choice. You will see plenty of strong reasons to choose recombinant antibodies over competing products. And we will pull occupations and persons that benefit from recombinant antibodies into the spotlight.
Next, we will present you with a distillation of a recent Nature Methods article that reports staggering and alarming findings in the literature related to traditional antibodies. To conclude, we will show what recombinant antibody expression can do to alleviate those issues.
Antibodies generated by means of recombinant technology offer several key benefits over traditional methods:
With the increasing availability of high quality antibodies, the range of important applications has broadened considerably in recent years. Various life-science and medicine related fields have a strong need for high quality recombinant antibodies. Examples are:
In short, the answer lies in recombinant antibodies advantages. Scientific progress has been exponentially increasing in recent years. Its need for increasingly specific tools and reagents is catered by the advent of recombinant technology.
Molecular biology techniques and its applications to antibody expression in vitro brought numerous benefits to biotechnology, life-sciences and medicine.
A recent article in Nature Methods features the increasing popularity of recombinant antibodies.1
The author highlights the fact that numerous older life-science publications, using catalogue antibodies derived from animals, suffer from reproducibility issues.
As a staggering example, the article notes a series of 15 publications with almost 70,000 primary and secondary citations that focus on a protein that is believed to be involved in amyotrophic lateral sclerosis and frontotemporal dementia.
Unbelievably, many researchers used antibodies that were found to not show relevant affinity or specificity to the protein in question. This example reveals the dire need for easily available high quality recombinant antibodies in the research community.
Subsequently, the author cites a report of the European Commission on the topic of antibodies. Antibodies can and should be produced without the use of animals, advises the EC report, and establishes that the obtained products are at least as well-performing as traditional antibodies.
Within 11 years since its foundation in 2010, evitria has become a leading service provider for recombinant antibody expression in CHO cells with a track record of over 11,000 antibodies delivered.
In addition, evitria has become efficient enough to be able to offer a record-setting five week time-scale and oftentimes finishes even faster.
Moreover, evitria enables its customers to access afucosylated antibodies through its exclusive licensing partnership to use ProBioGen’s GlymaxX (R) technology.
When asked about their impression of evitria, its customers reported back that they value evitria for its speed of processing, quality and purity of products, efficiency and pleasantness of cooperation.